These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 3717976)
41. Ultrasound as a screening procedure for methotrexate-induced hepatic damage in severe psoriasis. Miller JA; Dodd H; Rustin MH; Lees WR; Levene GM; Kirby JD; Munro DD Br J Dermatol; 1985 Dec; 113(6):699-705. PubMed ID: 3913457 [TBL] [Abstract][Full Text] [Related]
42. Hepatotoxicity of methotrexate in the treatment of psoriasis. Roenigk HH; Bergfeld WF; St Jacques R; Owens FJ; Hawk WA Arch Dermatol; 1971 Mar; 103(3):250-61. PubMed ID: 5548272 [No Abstract] [Full Text] [Related]
43. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. Rosenberg P; Urwitz H; Johannesson A; Ros AM; Lindholm J; Kinnman N; Hultcrantz R J Hepatol; 2007 Jun; 46(6):1111-8. PubMed ID: 17399848 [TBL] [Abstract][Full Text] [Related]
44. Clinical pharmacokinetics of methotrexate in psoriasis therapy. Hendel J Dan Med Bull; 1985 Dec; 32(6):329-37. PubMed ID: 3908004 [No Abstract] [Full Text] [Related]
45. Predictive value of HLA antigen for methotrexate-induced liver damage in patients with psoriasis. Pestana A; Halprin KM; Taylor JR; Schiff ER; Esquenazi V; Comerford M; Gomez C J Am Acad Dermatol; 1985 Jan; 12(1 Pt 1):26-9. PubMed ID: 3980800 [TBL] [Abstract][Full Text] [Related]
47. Nonlinear renal elimination kinetics of methotrexate due to saturation of renal tubular reabsorption. Hendel J; Nyfors A Eur J Clin Pharmacol; 1984; 26(1):121-4. PubMed ID: 6714284 [TBL] [Abstract][Full Text] [Related]
48. Monitoring patients on methotrexate: hepatic fibrosis not seen in patients with normal serum assays of aminoterminal peptide of type III procollagen. Maurice PD; Maddox AJ; Green CA; Tatnall F; Schofield JK; Stott DJ Br J Dermatol; 2005 Mar; 152(3):451-8. PubMed ID: 15787813 [TBL] [Abstract][Full Text] [Related]